New CAR T Cell Therapies Advance Clinical Trials, Research, Development Globally

Recent advances in CAR T cell therapies are showing promising developments across cancer treatment, particularly in addressing challenges with solid tumors and improving precision medicine. Researchers have pioneered an innovative method to create CAR T cells directly in patients using targeted lipid nanoparticles, potentially simplifying manufacturing and reducing costs. The Calibr-Skaggs Institute has initiated a phase 1 trial of a switchable CAR T therapy for advanced breast cancer, aiming to enhance targeting precision and safety in solid tumors. Meanwhile, a large study by MD Anderson Cancer Center identified three patient subgroups in large B-cell lymphoma that respond differently to CD19 CAR T therapy, providing a basis for more tailored treatment strategies. Additionally, CERo Therapeutics received FDA orphan drug designation for CER-1236, a novel engineered T cell therapy targeting acute myeloid leukemia, currently in phase 1 trials. Lastly, Captain T Cell GmbH joined Bayer Co.Lab’s incubator to accelerate development of next-generation TCR-T cell therapies for solid tumors, with clinical trials planned to start in 2027.